A role of enhanced receptor engagement in the evolution of a pandemic acute haemorrhagic conjunctivitis virus

Autor: Baggen, J, Hurdiss, DL, Zocher, G, Mistry, N, Roberts, RW, Slager, JJ, Guo, H, Van Vliet, ALW, Wahedi, M, Benschop, K, Duizer, E, De Haan, CAM, De Vries, E, Casasnovas, JM, De Groot, RJ, Arnberg, N, Stehle, T, Ranson, NA, Thibaut, HJ, Van Kuppeveld, FJM

Acute hemorrhagic conjunctivitis (AHC) is a painful, contagious eye disease, with millions of cases in the last decades. Coxsackievirus A24 (CV-A24) was not originally associated with human disease, but in 1970 a pathogenic “variant” (CV-A24v) em

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::057b7d0a1569e64905b595f34529c72f
https://eprints.whiterose.ac.uk/124791/1/ranson.pdf

Multiplexed multicolor antiviral assay amenable for high-throughput research.

Autor: Li LH; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.; Molecular Vaccinology and Vaccine Discovery group, Leuven, Belgium., Chiu W; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium., Huang YA; KU Leuven Department of Neuroscience, Research Group Neurophysiology, Laboratory for Circuit Neuroscience, Leuven, Belgium.; Vlaams Instituut voor Biotechnologie, Neuro-Electronics Research Flanders (NERF), Leuven, Belgium., Rasulova M; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy (TPVC), Leuven, Belgium., Vercruysse T; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy (TPVC), Leuven, Belgium.; AstriVax, Heverlee, Belgium., Thibaut HJ; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy (TPVC), Leuven, Belgium., Ter Horst S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.; Cerba Research, Rotterdam, The Netherlands., Rocha-Pereira J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium., Vanhoof G; Janssen Therapeutics Discovery, Janssen Pharmaceutica, NV, Beerse, Belgium., Borrenberghs D; Janssen Global Public Health, Janssen Pharmaceutica, NV, Beerse, Belgium., Goethals O; Janssen Global Public Health, Janssen Pharmaceutica, NV, Beerse, Belgium., Kaptein SJF; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium., Leyssen P; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium., Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium., Dallmeier K; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium. kai.dallmeier@kuleuven.be.; Molecular Vaccinology and Vaccine Discovery group, Leuven, Belgium. kai.dallmeier@kuleuven.be.

Publikováno v: Nature communications [Nat Commun] 2024 Jan 02; Vol. 15 (1), pp. 42. Date of Electronic Publication: 2024 Jan 02.

TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.

Autor: Baggen J; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium. Electronic address: jim.baggen@kuleuven.be., Jacquemyn M; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium., Persoons L; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium., Vanstreels E; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium., Pye VE; Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London NW1 1AT, UK., Wrobel AG; Structural Biology of Disease Processes Laboratory, Francis Crick Institute, London NW1 1AT, UK., Calvaresi V; Department of Chemistry, Britannia House, 7 Trinity Street, King's College London, London SE1 1DB, UK., Martin SR; Structural Biology of Disease Processes Laboratory, Francis Crick Institute, London NW1 1AT, UK., Roustan C; Structural Biology Science Technology Platform, Francis Crick Institute, London NW1 1AT, UK., Cronin NB; LonCEM Facility, Francis Crick Institute, London NW1 1AT, UK., Reading E; Department of Chemistry, Britannia House, 7 Trinity Street, King's College London, London SE1 1DB, UK., Thibaut HJ; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium., Vercruysse T; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium., Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, Leuven 3000, Belgium., De Smet F; KU Leuven Department of Imaging and Pathology, Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Leuven 3000, Belgium., Yee A; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA., Nivitchanyong T; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA., Roell M; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA., Franco-Hernandez N; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA., Rhinn H; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA., Mamchak AA; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA., Ah Young-Chapon M; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA., Brown E; Alector LLC, 131 Oyster Point Blvd. Suite 600, South San Francisco, CA 94080, USA., Cherepanov P; Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London NW1 1AT, UK; Department of Infectious Disease, Section of Virology, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK. Electronic address: peter.cherepanov@crick.ac.uk., Daelemans D; KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven 3000, Belgium. Electronic address: dirk.daelemans@kuleuven.be.

Publikováno v: Cell [Cell] 2023 Aug 03; Vol. 186 (16), pp. 3427-3442.e22. Date of Electronic Publication: 2023 Jul 07.

FLUIDOT: A Modular Microfluidic Platform for Single-Cell Study and Retrieval, with Applications in Drug Tolerance Screening and Antibody Mining.

Autor: Breukers J; Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium.; LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium., Ven K; Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium.; LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium.; MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium., Struyfs C; Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium., Ampofo L; Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium.; MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium.; PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium.; Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium., Rutten I; Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium.; LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium., Imbrechts M; MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium.; PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium.; Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium., Pollet F; Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium., Van Lent J; Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium., Kerstens W; Translational Platform Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium., Noppen S; Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium., Schols D; Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium., De Munter P; Department of Internal Medicine, University Hospitals Leuven, UZ Herestraat 49, Leuven, 3000, Belgium.; Laboratory for Clinical Infectious and Inflammatory Disorders, KU Leuven, UZ Herestraat 49, Leuven, 3000, Belgium., Thibaut HJ; Translational Platform Virology and Chemotherapy, Rega Institute, KU Leuven, Rega - Herestraat 49, Leuven, 3000, Belgium., Vanhoorelbeke K; MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium.; PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium.; Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Etienne Sabbelaan 53, Kortrijk, 8500, Belgium., Spasic D; Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium., Declerck P; MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium.; PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium.; Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium., Cammue BPA; Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium., Geukens N; MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium.; PharmAbs, The KU Leuven Antibody Center, KU Leuven, ON 2 Herestraat 49, Leuven, 3000, Belgium.; Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, ON2 Herestraat 49, Leuven, 3000, Belgium., Thevissen K; Centre of Microbial and Plant Genetics, KU Leuven, Kasteelpark Arenberg 20, Leuven, 3001, Belgium., Lammertyn J; Department of Biosystems, Biosensors group, KU Leuven, Willem de Croylaan 42, Leuven, 3001, Belgium.; LISCO, KU Leuven Institute for Single Cell Omics, ON4 Herestraat 49, Leuven, 3000, Belgium.; MabMine: KU Leuven Single B Cell Mining Platform, KU Leuven, ON2 Herestraat 49, 3000, Leuven, Belgium.; LIMNI, KU Leuven Institute for Micro- and Nanoscale Integration, Celestijnenlaan 200F, Leuven, 3001, Belgium.

Publikováno v: Small methods [Small Methods] 2023 Mar; Vol. 7 (3), pp. e2201477. Date of Electronic Publication: 2023 Jan 15.

Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.

Autor: Chiu W; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., Schepers J; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., Francken T; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., Vangeel L; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., Abbasi K; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., Jochmans D; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., De Jonghe S; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., Thibaut HJ; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, Gaston Geenslaan 2, 3001, Leuven, Belgium., Thiel V; Institute of Virology and Immunology (IVI), Bern, Switzerland; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Neyts J; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., Laporte M; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium., Leyssen P; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium. Electronic address: Pieter.leyssen@kuleuven.be.

Publikováno v: Antiviral research [Antiviral Res] 2023 Feb; Vol. 210, pp. 105506. Date of Electronic Publication: 2022 Dec 21.